Jun 02, 2020
Meditrina, Inc. completes $10M equity financing led by Deerfield
Jun 01, 2020
Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
May 29, 2020
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
May 22, 2020
The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019. The market is projected to grow at a CAGR of 12.1% from 2020 to 2027
May 12, 2020
Minerva Surgical® Announces Acquisition Closing of Boston Scientific Intrauterine Health Products
Apr 29, 2020
Sumitovant Biopharma Announces Publication of Myovant Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 Liberty Studies in Uterine Fibroids in Obstetrics & Gynecology
Apr 13, 2020
USA Fibroid Centers Now Offer the Safety and Convenience of Telemedicine Consultations During the COVID-19 Pandemic
Feb 25, 2020
FDA Takes New Steps to Increase the Safety of Laparoscopic Power Morcellators when used in Gynecologic Surgeries
Jan 27, 2020
Heavy Menstrual Bleeding (HMB) Study 2020: Epidemiology, Trends, Treatment, Unmet Needs, Marketed & Emerging Drugs, Case Reports, Market Outlook to 2028
Nov 08, 2019
Meditrina to Introduce Aveta(TM) System for Diagnostic and Therapeutic Hysteroscopy at 2019 AAGL
Aug 09, 2019
BioSpecifics Technologies Corp. Reports Second Quarter 2019 Financial and Operating Results
Aug 07, 2019
Women's Excellence in Obstetrics and Gynecology Welcomes Amber Elling, Nurse Practitioner, to The Practice
Aug 05, 2019
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
Jul 11, 2019
Midwest Institute for Non-Surgical Therapy Opens Unique Fibroid Center: Innovative Treatment of Large Fibroids Without Surgery
May 21, 2019
Vascular Interventions of Tampa acquires new name and logo
May 14, 2019
Roivant Statement on Positive Phase 3 Results from Myovant's LIBERTY 1 Study in Uterine Fibroids
May 10, 2019
BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results
Apr 02, 2019
Minimally invasive uterine fibroid treatment safer and as effective as surgical treatment
Apr 02, 2019
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results
Apr 01, 2019
Two Abstracts by The Center for Innovative GYN Care Selected for Presentation at the 2019 Society of Gynecologic Surgeons Annual Meeting